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The related NUAK1 and NUAK2 are members of the AMPK
(AMP-activated protein kinase) family of protein kinases that are
activated by the LKB1 (liver kinase B1) tumour suppressor kinase.
Recent work suggests they play important roles in regulating
key biological processes including Myc-driven tumorigenesis,
senescence, cell adhesion and neuronal polarity. In the present
paper we describe the first highly specific protein kinase inhibitors
of NUAK kinases namely WZ4003 and HTH-01-015. WZ4003
inhibits both NUAK isoforms (IC50 for NUAK1 is 20 nM and
for NUAK2 is 100 nM), whereas HTH-01-015 inhibits only
NUAK1 (IC50 is 100 nM). These compounds display extreme
selectivity and do not significantly inhibit the activity of 139 other
kinases that were tested including ten AMPK family members.
In all cell lines tested, WZ4003 and HTH-01-015 inhibit the
phosphorylation of the only well-characterized substrate, MYPT1
(myosin phosphate-targeting subunit 1) that is phosphorylated
by NUAK1 at Ser445. We also identify a mutation (A195T)
that does not affect basal NUAK1 activity, but renders it
∼50-fold resistant to both WZ4003 and HTH-01-015. Consistent
with NUAK1 mediating the phosphorylation of MYPT1 we find
that in cells overexpressing drug-resistant NUAK1[A195T], but
not wild-type NUAK1, phosphorylation of MYPT1 at Ser445 is
no longer suppressed by WZ4003 or HTH-01-015. We also
demonstrate that administration of WZ4003 and HTH-01-015
to MEFs (mouse embryonic fibroblasts) significantly inhibits
migration in a wound-healing assay to a similar extent as NUAK1-
knockout. WZ4003 and HTH-01-015 also inhibit proliferation
of MEFs to the same extent as NUAK1 knockout and U2OS
cells to the same extent as NUAK1 shRNA knockdown. We find
that WZ4003 and HTH-01-015 impaired the invasive potential
of U2OS cells in a 3D cell invasion assay to the same extent as
NUAK1 knockdown. The results of the present study indicate that
WZ4003 and HTH-01-015 will serve as useful chemical probes
to delineate the biological roles of the NUAK kinases.
Key words: AMP-activated protein kinase (AMPK), AMPK-re-
lated kinase 5 (ARK5), kinase inhibitor, kinase profiling, liver
kinase B1 (LKB1), myosin phosphate-targeting subunit
1(MYPT1), sucrose-non-fermenting protein kinase/AMPK-
related protein kinase (SNARK).
INTRODUCTION
NUAK family SNF1-like kinase-1 [NUAK1, also known as
ARK5 (AMPK-related kinase 5)] and the closely related NUAK2
[SNARK (SNF1/AMPK-related kinase)] are members of the
AMPK (AMP-activated protein kinase) family of protein kinases
that are activated by the LKB1 (liver kinase B1) tumour suppressor
protein kinase [1]. NUAK isoforms are ubiquitously expressed
and possess an N-terminal kinase domain (residues 55–306,
NUAK1), followed by a C-terminal region, which although
similar between NUAK1 and NUAK2, possesses no obvious
domains or homology with other proteins [2]. LKB1 triggers
the activation of NUAK isoforms by phosphorylating a specific
threonine residue within their T-loop (Thr211 in NUAK1 and
Thr208 in NUAK2). The other members of the AMPK family
activated by LKB1 include AMPKα isoforms, four MARK
(microtubule-affinity-regulating kinase) isoforms, three SIK (salt-
induced kinase) isoforms, two BRSK (brain-specific kinase)/SAD
isoforms and SNRK (SNF-related kinase), a testis-specific
enzyme [1,3]. AMPK family kinases play fundamental roles in
biology, including regulation of cellular energy levels (AMPKα)
[4], cell polarity (MARKs and BRSKs) [5,6], gene transcription
(SIKs) [7,8] and resolution of the immune system (SIKs) [8].
There is increasing interest in the NUAK kinases and studies
hint at roles in regulating cell adhesion [9,10], cancer cell
invasion [11–13], embryonic development [14,15], senescence
[16], proliferation [17], neuronal polarity and axon branching
[18]. A synthetic lethal siRNA screen also suggested that
NUAK1 operates as an essential survival factor in oncogenic
Myc-driven tumours and proposed that inhibitors of NUAK1
would have utility for treatment of such tumours [19]. However,
despite this flurry of activity, few concrete details are known
regarding the key substrates that NUAK isoforms phosphorylate
to influence these processes. Only a single substrate, namely the
MYPT1 (myosin phosphate-targeting subunit 1) PP1 (protein
phosphatase 1) regulatory subunit, has been reported thus far,
whose phosphorylation has been demonstrated to be reduced
in NUAK1-knockout MEFs (mouse embryonic fibroblasts) [10].
The NUAK1 and NUAK2 isoforms phosphorylate MYPT1 at
three conserved residues (Ser445, Ser472 and Ser910) following
conditions that induce cell detachment [10]. This promotes
interaction with 14-3-3 isoforms, interfering with the ability of
Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; BRSK, brain-specific kinase; DMEM, Dulbecco’s modified Eagle’s
medium; HA, haemagglutinin; HEK, human embryonic kidney; LKB1, liver kinase B1; MARK, microtubule-affinity-regulating kinase; MEF, mouse embryonic
fibroblast; MYPT1, myosin phosphate-targeting subunit 1; NF-κB, nuclear factor κB; PEI, polyethylenimine; PP1, protein phosphatase 1; SIK, salt-induced
kinase.
1 Correspondence may be addressed to either of these authors (email d.r.alessi@dundee.ac.uk or Nathanael_Gray@dfci.harvard.edu).
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the MYPT1–PP1 phosphatase complex to dephosphorylate the
myosin light chain [10]. Both isoforms of NUAK possess three
unique GILK motifs that interact with PP1, and this interaction is
essential for association of NUAK isoforms with MYPT1 [10]. It
is likely that both NUAK1 and NUAK2 isoforms phosphorylate
MYPT1 at Ser445 and that the residual phosphorylation of MYPT1
observed in NUAK1-knockout MEFs is mediated by NUAK2
[10].
In overexpression and in vitro studies, given the similarity in the
catalytic domains of AMPK family kinases, it is likely that these
kinases will phosphorylate non-physiological substrates normally
phosphorylated by other family members. To avoid having to
rely on in vitro and overexpression approaches, efforts have
commenced to develop selective AMPK family kinase inhibitors.
Early AMPK family inhibitors such as Compound C (also known
as dorsomorphin) [20] and BX-795 [10,19,21] inhibited all of
the AMPK family members tested, including NUAK isoforms,
with high potency. Subsequently, a BX-795 derivative termed
MRT67307 was described that exhibited greater specificity, but
nevertheless still inhibited SIK, NUAK and MARK isoforms
[22]. However, the recent discovery of two small molecules
termed KIN112 and HG-9-91-01 [8,23] that inhibit all three
SIK isoforms without significantly suppressing other AMPK
family kinases, offers encouragement that it will be feasible to
develop specific AMPK family inhibitors. In the present paper
we provide further evidence that this is indeed the case. We
report on two highly selective inhibitors termed WZ4003, which
inhibits both NUAK1 and NUAK2, and HTH-01-015,
which inhibits NUAK1 with >100-fold higher potency than
NUAK2. We show that WZ4003 and HTH-01-015 are capable
of suppressing MYPT1 phosphorylation in cells and phenocopy
knock out of NUAK1 in cell migration and adhesion analyses.
The results of the present study establish that HTH-01-015 and
WZ4003 comprise useful tools for probing the physiological
functions of the NUAK isoforms.
MATERIALS AND METHODS
Materials
The Sakamototide substrate peptide (ALNRTSSDSALHRRR)
was used as the NUAK1 and NUAK2 substrate in kinase assays
[10]. [γ -32P]ATP was from PerkinElmer. Protein G–Sepharose,
glutathione–Sepharose and an ECL kit was from GE Healthcare.
P81 phosphocellulose paper was from Whatman. Doxycycline,
DMSO, BSA and benzamidine were from Sigma–Aldrich. PMSF
was from Melford. Novex 4–12% polyacrylamide Bis-Tris gels,
LDS sample buffer, puromycin, hygromycin, blasticidin, PBS-
EDTA-based Cell Dissociation Buffer and other tissue culture
reagents were from Invitrogen Life Technologies. Instant Blue
Coomassie stain was from Expedeon. PEI (polyethylenimine) was
from Polysciences, and 1 M magnesium acetate solution was from
Fluka.
Antibodies
The following antibodies were raised in sheep and affinity-purified
on the appropriate antigen: anti-(MYPT1 p-Ser445) (residues 437–
452 of mouse, sequence RLGLRKTGS*YGALAEI, S508C, first
bleed), anti-MYPT1 [human MBP (maltose-binding protein)–
MYPT1, residues 714–1005, S662B, first bleed] and anti-
NUAK1 (human His–NUAK1, S628B, second bleed). Antibody
production was carried out under UK Home Office approved
guidelines. The commercial antibodies used in the present
paper are anti-ACC (acetyl-CoA carboxylase) (Cell Signaling
Technology, catalogue number 3662), anti-(ACC p-Ser79)
(Cell Signaling Technology, catalogue number 3661), anti-HA
(haemagglutinin)–peroxidase (3F10) (Roche, catalogue number
12013819001) and all HRP (horseradish peroxidase)-conjugated
secondary antibodies were obtained from Thermo Scientific.
General methods
All recombinant DNA procedures, electrophoresis, immunoblot-
ting, immunoprecipitation and tissue culture were performed
using standard protocols. NUAK1[A195T] mutagenesis was
performed using the QuikChange® site-directed mutagenesis
method (Stratagene) with KOD polymerase (Novagen).
DNA constructs used for transfection were purified from
Escherichia coli DH5α using Qiagen Maxi-prep kits according
to the manufacturer’s protocol. All DNA constructs were
verified by DNA sequencing, which was performed by
the Sequencing Service (MRC Protein Phosphorylation Unit,
College of Life Sciences, University of Dundee, Dundee,
U.K.; http://www.dnaseq.co.uk), using DYEnamic ET terminator
chemistry (GE Healthcare) on Applied Biosystems automated
DNA sequencers.
Cell culture, treatments and cell lysis
HEK (human embryonic kidney)-293 and U2OS cells
were cultured in DMEM (Dulbecco’s modified Eagle’s
medium) supplemented with 10% FBS, 2 mM glutamine
and 1×antibacterial/antimycotic solution. NUAK1+ / + and
NUAK1− / − MEFs were cultured in DMEM supplemented
with 10% (v/v) FBS and 2 mM glutamine, 1×antibacterial/
antimycotic solution, 1% (v/v) non-essential amino acids
and 1% (v/v) sodium pyruvate. HEK-293 Flp/In T-Rex cell
lines were cultured in DMEM supplemented with 10% (v/v)
FBS and 2 mM glutamine, 1×antibacterial/antimycotic solution,
100 μg/ml hygromycin and 15 μg/ml blasticidin. Supplementing
the culture medium with 0.1 μg/ml doxycycline for 16–24 h
induced protein expression in the HEK-293 Flp/In T-Rex
cells. Cell counting was carried out using Invitrogen Countess
following the manufacturer’s protocol. A cell-detachment assay
was carried out on HEK-293 cells using PBS-EDTA-based cell
dissociation buffer as described previously [10]. An inhibitor
dose-dependence assay was carried out by treating the cells
with various concentrations of the inhibitors as indicated in
the Figure legends. The inhibitors were dissolved in DMSO
and the total concentration of DMSO in the culture media
never exceeded 1%. Transient transfections of HEK-293 cells
were carried out using PEI [24]. Stable transfections were
carried out in HEK-293 Flp/In T-Rex cells (Invitrogen) following
the manufacturer’s protocol. Lentivirus-mediated knock down
of NUAK1 was carried out in U2OS cells using shRNA
constructs as described previously [10]. Post-treatment and/or
transfection, cells were lysed in lysis buffer containing 50 mM
Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1%Triton X-100,
50 mM NaF, 10 mM sodium 2-glycerophosphate, 5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 0.27 M sucrose,
1 mM benzamidine (added before lysis), 1 mM PMSF (added
before lysis) and 0.1% 2-mercaptoethanol (added before lysis).
Lysates were clarified by centrifugation at 16000 g for 15 min
at 4 ◦C and either used for further experiments or snap-frozen
in liquid nitrogen and stored at − 80 ◦C. Protein estimation was
carried out using the Bradford method with BSA as a standard.
IC50 determination
Active GST–NUAK1, GST–NUAK1[A195T] and GST–NUAK2
enzymes were purified using glutathione–Sepharose from HEK-
293 cell lysates 36–48 h following the transient transfection
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Figure 1 WZ4003, a specific NUAK1 and NUAK2 inhibitor
(A) Chemical structure of the NUAK1/NUAK2 inhibitor WZ4003. (B) Wild-type (WT) GST–NUAK1 and GST–NUAK2 were assayed using 200 μM Sakamototide in the presence of 100 μM [γ -32P]ATP
(∼500 c.p.m./pmol) with the indicated concentrations of WZ4003. The IC50 graph was plotted using GraphPad Prism software with non-linear regression analysis. The results are presented as
the percentage of kinase activity relative to the DMSO-treated control. Results are means +− S.D. for triplicate reactions with similar results obtained in at least one other experiment. (C) Kinase
profiling of the WZ4003 inhibitor at 1 μM was carried out against the panel of 140 kinases at the The International Centre for Protein Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/). AMPK
family kinases are indicated with an asterisk, LKB1 with a filled hexagon and NUAK1 with an arrow. The full names of the kinases can be found in the legend to Supplementary Table S1 (at
http://www.biochemj.org/bj/457/bj4570215add.htm). (D) Wild-type (WT) GST–NUAK1 and GST–NUAK1[A195T] were purified from HEK-293 cells following transient transfection and relative levels
of wild-type and mutant enzymes were analysed by Coomassie Blue staining of a polyacrylamide gel (bottom panel). Intrinsic kinase activities of the equivalent amounts of NUAK1 and NUAK1[A195T]
were compared by carrying out a quantitative kinase activity assay by calculating the relative kinase-mediated incorporation of [γ -32P]ATP into the Sakamototide substrate peptide. Values are
means +− S.D. for an experiment carried out in triplicate. (E) As in (B) except that WZ4003 comparative IC50 values were derived for wild-type (WT) GST–NUAK1 and GST-–NUAK1[A195T].
of pEBG2T mammalian constructs expressing N-terminal GST-
tagged NUAK1, NUAK1[A195T] or NUAK2. For peptide kinase
assays, 96-well plates were used, and each reaction was performed
in triplicate. Each reaction was set up in a total volume
of 50 μl containing 100 ng of NUAK1 (wild-type or A195T
mutant) or NUAK2 in 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA,
10 mM magnesium acetate, 200 μM Sakamototide, 0.1 mM [γ -
32P]ATP (450–500 c.p.m./pmol) and the indicated concentrations
of inhibitors dissolved in DMSO. After incubation for 30 min at
30 ◦C, reactions were terminated by adding 25 mM (final) EDTA
to chelate the magnesium. Then, 40 μl of the reaction mix was
spotted on to P81 paper and immersed in 50 mM orthophosphoric
acid. Samples were washed three times in 50 mM orthophosphoric
acid followed by a single acetone rinse and air drying. The
incorporation of [γ -32P]ATP into Sakamototide was quantified by
Cerenkov counting. The values were expressed as a percentage of
the DMSO control. IC50 curves were developed and IC50 values
were calculated using GraphPad Prism software.
Kinase activity assays
In vitro activities of purified GST–NUAK1 and GST–
NUAK1[A195T] were measured using Cerenkov counting
of incorporation of radioactive 32P from [γ -32P]ATP into
Sakamototide substrate peptide as described previously [10].
Reactions were carried out in a 50 μl reaction volume for 30 min
at 30 ◦C and reactions were terminated by spotting 40 μl of the
reaction mix on to P81 paper and immediately immersing in
50 mM orthophosphoric acid. Samples were washed three times
in 50 mM orthophosphoric acid followed by a single acetone rinse
and air drying. The kinase-mediated incorporation of [γ -32P]ATP
into Sakamototide was quantified by Cerenkov counting. One unit
of activity was defined as that which catalysed the incorporation
of 1 nmol of [32P]phosphate into the substrate over 1 h.
Wound-healing assay
MEFs were split and an approximately equal number of cells were
loaded into the left and right chambers of the IBIDI Self-Insertion
Inserts (catalogue number 80209). Each insert was placed in
one well of a 12-well plate and the cells were seeded with or
without treatment with the inhibitors. For the comparison of the
migration properties of different MEFs on the same video, a single
insert was used and an equal number of MEFs were counted and
loaded on either chamber of the same insert. To study the effect of
inhibitors on cell migration, wound-healing assays on MEFs were
also carried out on separate inserts with or without treatment with
a 10 μM concentration of WZ4003 or HTH-01-015. Inhibitors
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Figure 2 HTH-01-015, a specific NUAK1 inhibitor
(A) Chemical structure of the NUAK1-specific inhibitor HTH-01-015. (B) Wild-type (WT) GST–NUAK1 and GST–NUAK2 were assayed using 200 μM Sakamototide in the presence of 100 μM
[γ -32P]ATP (∼500 c.p.m./pmol) with the indicated concentrations of HTH-01-015. The IC50 graph was plotted using Graphpad Prism software with non-linear regression analysis. The results are
presented as the percentage of kinase activity relative to the DMSO-treated control. Results are means +− S.D. for triplicate reactions with similar results obtained in at least one other experiment. (C) Kinase
profiling of the HTH-01-015 inhibitor at 1 μM was carried out against the panel of 140 kinases at the The International Centre for Protein Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/).
AMPK family kinases are indicated with an asterisk, LKB1 with a filled hexagon and NUAK1 with an arrow. The full names of the kinases can be found in the legend to Supplementary Table S1 (at
http://www.biochemj.org/bj/457/bj4570215add.htm). (D) As in (B) except that HTH-01-015 comparative IC50 values were derived for wild-type (WT) GST–NUAK1 and GST–NUAK1[A195T].
were added to the cells 1 h before the start of the migration assay.
The experiments were carried out in triplicate. After overnight
incubation at 37 ◦C and 5% CO2, the insert was removed and the
migration of cells into the 500 μm gap between the chambers
was observed. The wound-gap healing properties of the cells
were observed over a period of 15–20 h under a Nikon Eclipse
Ti microscope with images taken every 2 min by a Photometrics
cascade II CCD (charge-coupled device) camera using Nikon NIS
Elements software.
Cell proliferation assay
Cell proliferation assays were carried out colorimetrically
in 96-well plates using the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay kit (Promega) following the
manufacturer’s protocol. Initially, 2000 cells per well were seeded
for U2OS cells and 3000 cells per well were seeded for MEFs. The
proliferation assays were carried out over 5 days in the presence
or absence of 10 μM HTH-01-015 or WZ4003.
Cell invasion assay
The ability of U2OS cells to invade in the presence or absence
of 10 μM HTH-01-015 or WZ4003 was tested in a growth-
factor-reduced MatrigelTM invasion chamber (BD Biosciences,
catalogue number 354483) as described previously [25]. Cells
were serum-deprived for 2 h, detached using cell-dissociation
buffer (Gibco), and 2.5×105 cells suspended in DMEM containing
1% (w/v) BSA were added to the upper chambers in triplicate
and chemoattractant [DMEM containing 10% (v/v) FBS] was
added to the lower wells. The chambers were kept at 37 ◦C in 5%
CO2 for 16 h in the presence or absence of 10 μM HTH-01-015
or WZ4003 both in the upper and lower wells. Non-invaded cells
were removed from the upper face of the filters by scraping, and
cells that had migrated to the lower face of the filters were fixed and
stained with Reastain Quick-Diff kit (Reagena) and images (×10
magnification) were captured. For cell invasion assays, statistical
significance was assessed using GraphPad Prism 5.0.
Protein kinase profiling
Kinase inhibitor specificity profiling assays were carried out at
The International Centre for Protein Kinase Profiling (http://www.
kinase-screen.mrc.ac.uk/) against a panel of 140 protein kinases
as described previously [26,27]. Results are presented as a
percentage of kinase activity in DMSO control reactions.
Protein kinases were assayed in vitro with 0.1 or 1 μM of the
inhibitors and the results are presented as an average of triplicate
reactions +− S.D. or in the form of comparative histograms.
RESULTS
WZ4003 is a dual inhibitor of NUAK1 and NUAK2
The NUAK inhibitors reported in the present paper were obtained
by re-purposing, in the case of WZ4003, or re-optimization,
in the case of HTH-01-015, of known compounds. The report
that BX795 [28], a tri-substituted pyrimidine whose primary
targets are TBK1 {TANK [TRAF (tumour-necrosis-factor-
receptor-associated factor)-associated NF-κB (nuclear factor-κB)
activator]-binding kinase 1} and IKKε [IκB (inhibitor of NF-
κB) kinase ε], inhibits NUAK1 [21,29] inspired us to evaluate
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Figure 3 XMD-17-51, a potent semi-specific NUAK1 inhibitor
(A) Chemical structure of XMD-17-51. (B) Wild-type (WT) GST–NUAK1 and GST–NUAK1[A195T] were assayed using 200 μM Sakamototide in the presence of 100 μM [γ -32P]ATP
(∼500 c.p.m./pmol) with the indicated concentrations of XMD-17-51. The IC50 graph was plotted using Graphpad Prism software with non-linear regression analysis. The results are presented
as the percentage of kinase activity relative to the DMSO-treated control. Results are means +− S.D. for triplicate reactions with similar results obtained in at least one other experiment. (C) Kinase
profiling of the XMD-17-51 inhibitor at 1 μM was carried out against the panel of 140 kinases at the The International Centre for Protein Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/).
AMPK family kinases are indicated with an asterisk, LKB1 with a filled hexagon and NUAK1 with an arrow. The full names of the kinases can be found in the legend to Supplementary Table S1 (at
http://www.biochemj.org/bj/457/bj4570215add.htm). (D) HEK-293 cells were treated in the absence (DMSO) or presence of the indicated concentrations of XMD-17-51 over 16 h. Cell medium
was then replaced with either normal DMEM containing no EDTA-PBS-based cell dissociation buffer ( − ) or EDTA-PBS-based cell dissociation buffer ( + ) containing the same concentration of
XMD-17-51 that the cells were previously incubated in. Cell detachment was induced with gentle tapping of the plates followed by gentle centrifugation at 70 g for 3 min. Cells were lysed immediately
after removal of the supernatant. Endogenous MYPT1 was immunoprecipitated from 0.5 mg of the cell lysates. The immunoprecipitates were immunoblotted for the detection of p-Ser445 MYPT1 and
total MYPT1. The cell lysates were subjected to immunoblotting for the detection of p-Ser79 ACC and total ACC. Similar results were obtained in three separate experiments.
NUAK inhibitory activity of our collection of 2,4,5-tri-substituted
pyrimidines. WZ4003 was identified from this effort [30]. HTH-
01-015 was derived from LRRK2-IN [31] and related pyrimido-
diazepines previously reported by us to have a weak inhibitory
effect against NUAK1 [32]. The chemical synthesis schemes used
to generate and characterize each of the compounds used in the
present study is detailed in the Supplementary Online Data (at
http://www.biochemj.org/bj/457/bj4570215add.htm).
The structure of WZ4003 is shown in Figure 1(A). It inhibits
NUAK1 with an IC50 of 20 nM (Figure 1B) and NUAK2 with an
IC50 of 100 nM (Figure 1B). To evaluate the specificity of WZ4003
we studied the effect that this compound has on the activity
of 140 protein kinases, including ten AMPK-related kinase
family members most closely related to NUAK1 (Figure 1C
and Supplementary Table S1 at http://www.biochemj.org/bj/
457/bj4570215add.htm). WZ4003 was remarkably specific and,
apart from NUAK1 and NUAK2, did not significantly inhibit ten
other AMPK-related kinases or other kinases tested, including
LKB1 at a concentration of 1 μM (10-fold higher than the IC50 of
inhibition of NUAK1).
HTH-01-015 is a selective inhibitor of NUAK1
The structure of HTH-01-015 is shown in Figure 2(A). It
inhibits NUAK1 with an IC50 of 100 nM (Figure 2B), but, unlike
WZ4003, does not significantly inhibit NUAK2 (IC50 of >10 μM)
(Figure 2B). HTH-01-015 was similarly specific to WZ4003 and,
apart from NUAK1, did not markedly suppress the activity of
any of the other 139 protein kinases evaluated (Figure 2C and
Supplementary Table S1).
We also generated two further analogues of HTH-01-015,
namely XMD-17-51 (Figure 3A) and XMD-18-42 (Figure 4A),
that inhibited NUAK1 more potently than HTH-01-015. XMD-
17-51 inhibited NUAK1 with an IC50 of 1.5 nM (Figure 3B)
and XMD-18-42 inhibited NUAK1 with an IC50 of 30 nM
(Figure 4B). Neither compound significantly inhibited NUAK2
(results not shown). However, XMD-17-51 and XMD-18-42
were less selective than WZ4004 and HTH-01-015 and inhibited
kinases involved in growth and proliferation, such as Aurora
isoforms, ABL (Abelson tyrosine-protein kinase 1) and JAK2
(Janus kinase 2) (Figures 3C and 4C). XMD-17-51 also inhibited
several AMPK family members (MARK1, MARK3, BRSK1 and
AMPK) (Figure 3C).
Development of inhibitor-resistant NUAK1 mutants
Previous work revealed that in other kinases, such as PKA (cAMP-
dependent protein kinase) [33], ROCK (Rho-associated kinase)
[33] and LRRK2 (leucine-rich repeat kinase 2) [31,34], mutation
of the alanine residue that resides before the conserved subdomain
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Figure 4 XMD-18-42, a semi-specific NUAK1 inhibitor
(A) Chemical structure of XMD-18-42. (B) Wild-type (WT) GST–NUAK1 and GST–NUAK1[A195T] were assayed using 200 μM Sakamototide in the presence of 100 μM [γ -32P]ATP (∼500
c.p.m./pmol) with the indicated concentrations of XMD-18-42. The IC50 graph was plotted using Graphpad Prism software with non-linear regression analysis. The results are presented as the
percentage of kinase activity relative to the DMSO-treated control. Results are means +− S.D. for triplicate reactions with similar results obtained in at least one other experiment. (C) Kinase profiling
of the XMD-18-42 inhibitor at 1 μM was carried out against the panel of 140 kinases at the The International Centre for Protein Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/). AMPK
family kinases are indicated with an asterisk, LKB1 with a filled hexagon and NUAK1 with an arrow. The full names of the kinases can be found in the legend to Supplementary Table S1 (at
http://www.biochemj.org/bj/457/bj4570215add.htm). (D) HEK-293 cells were treated in the absence (DMSO) or presence of the indicated concentrations of XMD-18-42 over 16 h. Cell medium
was then replaced with either normal DMEM containing no EDTA-PBS-based cell dissociation buffer ( − ) or EDTA-PBS-based cell dissociation buffer ( + ) containing the same concentration of
XMD-18-42 that the cells were previously incubated in. Cell detachment was induced with gentle tapping of the plates followed by gentle centrifugation at 70 g for 3 min. Cells were lysed immediately
after removal of the supernatant. Endogenous MYPT1 was immunoprecipitated from 0.5 mg of the cell lysates. The immunoprecipitates were immunoblotted for the detection of p-Ser445 MYPT1 and
total MYPT1. The cell lysates were subjected to immunoblotting for the detection of p-Ser79 ACC and total ACC. Similar results were obtained in three separate experiments.
VII magnesium ion-binding DFG motif to a threonine residue,
introduces a steric clash with certain ATP-competitive inhibitors
without affecting the intrinsic specific kinase activity. As NUAK
isoforms also possess an alanine residue at the equivalent
position (Ala195), we mutated this residue to a threonine residue.
Importantly, this mutation did not inhibit NUAK1 specific activity
(Figure 1D), but markedly reduced the potency of WZ4003
(45-fold, Figure 1E) and HTH-01-015 (∼60-fold, Figure 2D).
The A195T mutation also rendered NUAK1 >50-fold resistant
to the more potent, but less selective, XMD-17-51 (Figure 3C)
and XMD-18-42 (Figure 4C) NUAK1 inhibitors.
WZ4003 and HTH-01-015 suppress NUAK1-mediated MYPT1
phosphorylation
To evaluate whether WZ4003 and HTH-01-015 could suppress
NUAK activity in vivo, we treated HEK-293 cells with increasing
concentrations of either inhibitor and assessed its effect on
MYPT1 phosphorylation at Ser445, one of the major sites of
NUAK1 phosphorylation [10]. We treated HEK-293 cells with
EDTA to induce detachment and phosphorylation of Ser445 [10],
and observed that WZ4003 suppressed MYPT1 phosphorylation
in a dose-dependent manner, with maximal effects observed at
inhibitor concentrations of 3–10 μM (Figure 5A). As HEK-293
cells express NUAK1 as well as NUAK2, and previous work
suggests that both of these kinases interact and phosphorylate
MYPT1 [10], it is likely that a NUAK1-selective inhibitor would
not suppress MYPT1 phosphorylation to the same extent as the
dual NUAK isoform inhibitor. Consistent with this we found that
treatment of cells with 10 μM HTH-01-015, the NUAK1 isoform
selective inhibitor, only led to a partial inhibition of MYPT1
phosphorylation (Figure 5B). The other compounds, XMD-17-51
(Figure 3D) and XMD-18-42 (Figure 4D), that potently inhibit
NUAK1 but not NUAK2, also only partially suppressed MYPT1
phosphorylation.
EDTA-triggered cell detachment also potently activates AMPK
[10] and therefore induces phosphorylation of one of its substrates,
ACC, at Ser79 [35]. Consistent with the screening data indicating
that WZ4003 and HTH-01-015 do not inhibit AMPK, we obser-
ved that neither compound inhibited phosphorylation of ACC at
Ser79 induced by cell detachment (Figures 5A and 5B).
To obtain further evidence that the WZ4003 and HTH-01-015
compounds inhibited NUAK activity in vivo, we generated HEK-
293 cells that stably overexpress inhibitor-sensitive wild-type
HA–NUAK1 or inhibitor-resistant HA–NUAK1[A195T] cells.
Quantitative immunoblot analysis revealed that the wild-type and
mutant NUAK1 were expressed ∼150-fold and ∼75-fold higher
respectively than endogenous NUAK1 (Supplementary Figure
S1 at http://www.biochemj.org/bj/457/bj4570215add.htm). Strik-
ingly, in cells expressing drug-resistant NUAK1[A195T], we
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Figure 5 HTH-01-015 and WZ4003 inhibit MYPT1 Ser445 phosphorylation in vivo
(A) HEK-293 cells were treated in the absence (DMSO) or presence of the indicated concentrations of WZ4003 over 16 h. Cell medium was then replaced with either normal DMEM containing
no EDTA-PBS-based cell dissociation buffer ( − ) or EDTA-PBS-based cell dissociation buffer ( + ) containing the same concentration of WZ4003 that the cells were previously incubated in. Cell
detachment was induced with gentle tapping of the plates followed by gentle centrifugation at 70 g for 3 min. Cells were lysed immediately after removal of the supernatant. Endogenous MYPT1
was immunoprecipitated from 0.5 mg of the cell lysates. The immunoprecipitates were immunoblotted for the detection of p-Ser445 MYPT1 and total MYPT1. The cell lysates were subjected to
immunoblotting for the detection of p-Ser79 ACC and total ACC. Similar results were obtained in three separate experiments. (B) As in (A) except for the HTH-01-015 inhibitor was used. (C–F) As
above except that HEK-293 Flp/In T-Rex cells stably expressing the indicated wild-type HA-tagged NUAK1 or drug-resistant HA-tagged NUAK1[A195T] were used. Similar results were obtained in
three separate experiments for all data shown on this Figure.
observed that even at very high concentrations of 30 μM,
WZ4003 (Figure 5D) or HTH-01-015 (Figure 5F) failed to
block MYPT1 Ser445 phosphorylation. In contrast, in HEK-293
cells expressing wild-type NUAK1, concentrations of 3–10 μM
WZ4003 (Figure 5C) or HTH-01-015 (Figure 5E) markedly
suppressed phosphorylation of MYPT1.
WZ4003 and HTH-01-015 suppresses cell migration
Previous work suggested that RNAi-mediated knock down
of NUAK1 promoted cell adhesion [10], which would be
expected to inhibit cell migration. To investigate this further
with a view to assessing whether NUAK inhibitors would
inhibit migration, we first compared the migration of wild-type
(NUAK1+ / + ) and homozygous NUAK1-knockout (NUAK1− / − )
MEFs using a 2D wound-healing assay. Consistent with
NUAK1− / − MEFs being more adhesive, we found that they
migrated slower than wild-type cells and presented a more
‘flattened’ adherent phenotype (Figure 6A). A movie comparing
migration of the NUAK1+ / + and NUAK1− / − MEFs also
highlights the strikingly reduced motility and more compressed
phenotype of the NUAK1− / − MEFs (Supplementary Movie
S1 at http://www.biochemj.org/bj/457/bj4570215add.htm). This
phenotype could be largely rescued by retroviral overexpression
of NUAK1+ / + into NUAK1− / − MEFs (Supplementary Movie S2
at http://www.biochemj.org/bj/457/bj4570215add.htm). We next
investigated whether the WZ4003 and HTH-01-015 inhibitors
could inhibit cell migration and observed that treatment of
NUAK1+ / + MEFs with 10 μM WZ4003 or HTH-01-015
markedly reduced cell migration in the wound-healing assay
(Figure 6B).
WZ4003 and HTH-01-015 inhibit cell proliferation
Previous studies have suggested that inhibiting NUAK1 would
suppress proliferation [17]. We therefore checked whether
NUAK1 inhibition by 10 μM WZ4003 or HTH-01-015 impaired
the proliferation of U2OS cells (Figures 7A and 7B) or MEFs
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Figure 6 NUAK1 inhibition suppresses cell migration
(A) NUAK1+ / + and NUAK1− / − MEFs were split into the chambers (as described in the Materials and methods section). The inserts were then removed and a wound-healing assay was carried out
in triplicate. Snapshots at specific time points from time-lapse microscopy were used as representative images for comparison between the migration properties of NUAK1+ / + and NUAK1− / −
MEFs. (B) The migration assay of NUAK1+ / + MEFs treated with or without 10 μM WZ4003 or HTH-01-015 was carried out as in (A).
(Figures 7C and 7D). In U2OS cells we found that either inhibitor
suppressed proliferation (Figure 7A) and phosphorylation of
MYPT1 (Figure 7B) to the same extent as shRNA-mediated
NUAK1 knockdown. In MEFs we also observed that treatment
with 10 μM WZ4003 or HTH-01-015 suppressed proliferation
(Figure 7C) and phosphorylation of MYPT1 (Figure 7D) to the
same extent as NUAK1-knockout.
WZ4003 and HTH-01-015 inhibit U2OS cell invasion
Previous work has implicated NUAK1 in controlling the invasive
ability of various cell types [11–13]. To test whether NUAK1
inhibition impaired the ability of the invasive U2OS cells to enter
a matrix, we used a 3D MatrigelTM Transwell® invasion assay
[36]. These assays demonstrated that 10 μM WZ4003 or HTH-
01-015 markedly inhibited the invasiveness of U2OS cells in this
assay (Figure 8).
DISCUSSION
WZ4003 and HTH-01-015 are remarkably selective NUAK
kinase inhibitors, and do not significantly inhibit the activity
of any of the 139 other protein kinases we have investigated
(Figures 1 and 2). Consistent with WZ4003 and HTH-01-015
targeting NUAK1 in vivo, we observe that these compounds
inhibited MYPT1 Ser445 phosphorylation as well as cell migration,
invasion and proliferation to a similar extent as knock out
in MEFs or knock down in U2OS cells of NUAK1. The
identification of the A195T mutation that renders NUAK1
∼50-fold resistant to WZ4003 and HTH-01-015 also provides
an important approach to validate that biological effects
of these compounds are indeed mediated through inhibition of
NUAK1 rather than through an off-target effect. Although as
a proof of concept, we have shown that overexpression of the
NUAK1[A195T] mutant, but not wild-type NUAK1, renders
MYPT1 phosphorylation resistant to WZ4003 and HTH-01-015,
this approach is not ideal, as the overexpression of NUAK1 has the
potential to have an impact on biological processes by inducing
non-physiological phosphorylation of cellular proteins. In future
work we would recommend that gene-editing technologies be
deployed to generate an endogenous NUAK1[A195T] knock-
in mutation. Such knock-in cell lines should be rendered
greatly resistant to the WZ4003 and HTH-01-015 inhibitors and
therefore any effects that these compounds have that is mediated
through inhibition of NUAKs should be suppressed by this
mutation.
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Figure 7 NUAK1 inhibition suppresses cell proliferation
(A) U2OS cells were incubated with or without 10 μM WZ4003 or 10 μM HTH-01-015 and a cell proliferation assay was carried out over 5 days in triplicate using the CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay kit (Promega) (as described in the Materials and methods section). U2OS cells in which NUAK1 has been knocked-down using two different shRNA hairpins
were used in parallel as controls. The efficiency of the knock down of each shRNA is shown in top panel. SCR, control scrambled shRNA hairpin; shNUAK1 (1), first NUAK1 shRNA hairpin; shNUAK1
(2), second NUAK1 shRNA hairpin. (B) U2OS cells were treated with ( + ) or without ( − ) 10 μM WZ4003 or 10 μM HTH-01-015. After 16 h cell media was removed and cells were treated with
EDTA-PBS-based cell dissociation buffer supplemented with 10 μM WZ4003, 10 μM HTH-01–015 or DMSO for 20 min. Cell detachment was induced with gentle tapping of the plates followed
by gentle centrifugation at 70 g for 3 min. Cells were lysed immediately after removal of the media and immunoblotted for the detection of the indicated antibodies. (C and D) As above, except
NUAK1+ / + and NUAK1− / − MEFs were used. Similar results were obtained in three separate experiments.
The IC50 values of the WZ4003 and HTH-01-015 compounds
for inhibiting NUAK1 are in the range 20–100 nM when assayed
at 0.1 mM ATP in vitro. On the basis of the structures of these
compounds, it is likely that they are acting as ATP-competitive
inhibitors. As concentrations of ATP in cells are over 20-fold
higher than our in vitro assays, this is likely to account for
why relatively high concentrations of 3–10 μM WZ4003 and
HTH-01-015 are required to maximally suppress MYPT1 Ser445
phosphorylation in vivo. We have devoted considerable effort
to generate more potent NUAK1 inhibitors and have indeed
identified two analogues of HTH-01-015, namely XMD-17-51
and XMD-18-42, that inhibit NUAK1 with greater potency.
However, these compounds suffer from the drawback that they
are less selective than WZ4003 and HTH-01-015 and inhibit other
kinases implicated in controlling cell growth and proliferation
(Figures 3 and 4). XMD-17-51 also partially suppresses several
other AMPK family kinases (Figure 3).
WZ4003 inhibits both NUAK1 and NUAK2, whereas
HTH-01-015, as well as the more potent XMD-17-51 and
XMD-18-42 derivatives, are NUAK1-specific inhibitors. It is
currently unknown whether NUAK1 and NUAK2 have redundant
roles in vivo. Therefore comparing the effects of WZ4003
with NUAK1-selective inhibitors could provide insights into
the relative contributions of NUAK isoforms in mediating
physiological processes. In vitro NUAK1 and NUAK2 are equally
efficient at phosphorylating MYPT1 at Ser445 and both isoforms
interact similarly with the MYPT1–PP1 complex [10]. On the
basis of this, it is likely that compounds such as HTH-01-
015, which do not inhibit NUAK2, would not suppress MYPT1
phosphorylation to the same extent as the dual NUAK isoform
inhibitors. This is indeed what we observe (Figures 5A and 5B,
see also Figures 3D and 4D). In future work it would also be
interesting to undertake crystallographic analysis of the binding
of specific inhibitors to NUAK isoforms in order to elucidate
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Figure 8 NUAK1 inhibition suppresses invasion potential
U2OS cells treated without (DMSO) or with 10 μM WZ4003 or 10 μM HTH-01-015 were plated
on to a Transwell® invasion assay plate in triplicate using 10 % FBS as a chemoattractant. Cells
that had invaded through to the lower face of the filters were fixed and photographed (×10
magnification). The cells that migrated were counted and the data are presented as the mean
number of migrated cells +− S.D. U2OS cells with NUAK1-knockdown were used in parallel as a
control. Similar results were obtained in two separate experiments with each condition analysed
in triplicate.
the structural basis for the high specificity and isoform selectivity
of WZ4003 and HTH-01-015 compounds. Such knowledge might
also help with designing more potent NUAK1 inhibitors that retain
high selectivity.
Most importantly, the results of the present study indicate
that WZ4003 and HTH-01-015 represent useful chemical probes
to dissect the physiological roles of the NUAK kinases. In
future studies we would advocate undertaking studies using both
structurally diverse WZ4003 and HTH-01-015 inhibitors that
could give insight into the relative contributions of NUAK1 and
NUAK2 in controlling physiological processes. We also propose
that inhibitor-resistant NUAK1[A195T] mutants be deployed to
ensure any biological effects arising from NUAK1 inhibitors is
indeed desensitized by this mutation. In future studies it will be
exciting to establish the effects that WZ4003 and HTH-01-015
have on biological process recently proposed to be controlled by
NUAK isoforms, such as Myc-driven tumour cells [19], neuronal
polarity [18] and melanoma cell adhesion [11].
AUTHOR CONTRIBUTION
Sourav Banerjee undertook the experiments shown in Figures 1(B), 1(D), 1(E), 2(B),
2(D), 3(B), 3(D), 4(B) and 4(D), all data in Figures 5–8, Supplementary Figure S1 and
Supplementary Movies. Sara Buhrlage, Hai-Tsang Huang, Xianming Deng, Wenjun Zhou
and Jinhua Wang elaborated and synthesized all chemicals described in Figures 1–4
and described in Supplementary Scheme S1. Ryan Traynor undertook all kinase profiling
shown in Figures 1(C), 2(C), 3(C), 4(C) and Supplementary Table S1. Alan Prescott
performed the microscopy analysis in Figure 6 and Supplementary Movies. Sourav
Banerjee, Sara Buhrlage, Nathanael Gray and Dario Alessi planned the experiments,
analysed the experimental data and wrote the paper.
ACKNOWLEDGEMENTS
We thank Dr Mariko Hirano and Dr Shinichi Aizawa (RIKEN, Kobe, Japan) for providing us
with NUAK1-knockout MEFs. We also acknowledge the excellent technical support of the
MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) DNA Sequencing Service
(co-ordinated by Nicholas Helps), the MRC-PPU tissue culture team (co-ordinated by
Kirsten Airey and Janis Stark), and the Division of Signal Transduction Therapy (DSTT)
antibody purification teams (co-ordinated by Hilary McLauchlan and James Hastie).
FUNDING
This work was supported by the Medical Research Council (to D.R.A.), the pharmaceutical
companies supporting the Division of Signal Transduction Therapy Unit (AstraZeneca,
Boehringer-Ingelheim, GlaxoSmithKline, Merck KgaA, Janssen Pharmaceutica and Pfizer)
(to D.R.A.), Linde Family Foundation (to N.S.G.) and Friends for Life (to N.S.G.).
REFERENCES
1 Lizcano, J. M., Goransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley,
S. A., Udd, L., Makela, T. P., Hardie, D. G. and Alessi, D. R. (2004) LKB1 is a master
kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J.
23, 833–843
2 Alessi, D. R., Sakamoto, K. and Bayascas, J. R. (2006) LKB1-dependent signaling
pathways. Annu. Rev. Biochem. 75, 137–163
3 Jaleel, M., McBride, A., Lizcano, J. M., Deak, M., Toth, R., Morrice, N. A. and Alessi, D. R.
(2005) Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1
substrate. FEBS Lett. 579, 1417–1423
4 Hardie, D. G., Ross, F. A. and Hawley, S. A. (2012) AMPK: a nutrient and energy sensor
that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251–262
5 Matenia, D. and Mandelkow, E. M. (2009) The tau of MARK: a polarized view of the
cytoskeleton. Trends Biochem. Sci. 34, 332–342
6 Kishi, M., Pan, Y. A., Crump, J. G. and Sanes, J. R. (2005) Mammalian SAD kinases are
required for neuronal polarization. Science 307, 929–932
7 Screaton, R. A., Conkright, M. D., Katoh, Y., Best, J. L., Canettieri, G., Jeffries, S., Guzman,
E., Niessen, S., Yates, 3rd, J. R., Takemori, H. et al. (2004) The CREB coactivator TORC2
functions as a calcium- and cAMP-sensitive coincidence detector. Cell 119, 61–74
8 Clark, K., MacKenzie, K. F., Petkevicius, K., Kristariyanto, Y., Zhang, J., Choi, H. G.,
Peggie, M., Plater, L., Pedrioli, P. G., McIver, E. et al. (2012) Phosphorylation of CRTC3
by the salt-inducible kinases controls the interconversion of classically activated and
regulatory macrophages. Proc. Natl. Acad. Sci. U.S.A. 109, 16986–16991
9 Vallenius, T., Vaahtomeri, K., Kovac, B., Osiceanu, A. M., Viljanen, M. and Makela, T. P.
(2011) An association between NUAK2 and MRIP reveals a novel mechanism for
regulation of actin stress fibers. J. Cell Sci. 124, 384–393
10 Zagorska, A., Deak, M., Campbell, D. G., Banerjee, S., Hirano, M., Aizawa, S., Prescott,
A. R. and Alessi, D. R. (2010) New roles for the LKB1-NUAK pathway in controlling
myosin phosphatase complexes and cell adhesion. Sci. Signaling 3, ra25
11 Bell, R. E., Khaled, M., Netanely, D., Schubert, S., Golan, T., Buxbaum, A., Janas, M. M.,
Postolsky, B., Goldberg, M. S., Shamir, R. and Levy, C. (2013) Transcription
factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1.
J. Invest. Dermatol., doi:10.1038/jid.2013.340
12 Kusakai, G., Suzuki, A., Ogura, T., Kaminishi, M. and Esumi, H. (2004) Strong association
of ARK5 with tumor invasion and metastasis. J. Exp. Clin. Cancer Res. 23, 263–268
13 Lu, S., Niu, N., Guo, H., Tang, J., Guo, W., Liu, Z., Shi, L., Sun, T., Zhou, F., Li, H. et al.
(2013) ARK5 promotes glioma cell invasion, and its elevated expression is correlated with
poor clinical outcome. Eur. J. Cancer 49, 752–763
14 Hirano, M., Kiyonari, H., Inoue, A., Furushima, K., Murata, T., Suda, Y. and Aizawa, S.
(2006) A new serine/threonine protein kinase, Omphk1, essential to ventral body wall
formation. Dev. Dyn. 235, 2229–2237
15 Ohmura, T., Shioi, G., Hirano, M. and Aizawa, S. (2012) Neural tube defects by NUAK1
and NUAK2 double mutation. Dev. Dyn. 241, 1350–1364
16 Humbert, N., Navaratnam, N., Augert, A., Da Costa, M., Martien, S., Wang, J., Martinez,
D., Abbadie, C., Carling, D., de Launoit, Y. et al. (2010) Regulation of ploidy and
senescence by the AMPK-related kinase NUAK1. EMBO J. 29, 376–386
17 Hou, X., Liu, J. E., Liu, W., Liu, C. Y., Liu, Z. Y. and Sun, Z. Y. (2011) A new role of
NUAK1: directly phosphorylating p53 and regulating cell proliferation. Oncogene 30,
2933–2942
18 Courchet, J., Lewis, Jr, T. L., Lee, S., Courchet, V., Liou, D. Y., Aizawa, S. and Polleux, F.
(2013) Terminal axon branching is regulated by the LKB1-NUAK1 kinase pathway via
presynaptic mitochondrial capture. Cell 153, 1510–1525
19 Liu, L., Ulbrich, J., Muller, J., Wustefeld, T., Aeberhard, L., Kress, T. R., Muthalagu, N.,
Rycak, L., Rudalska, R., Moll, R. et al. (2012) Deregulated MYC expression induces
dependence upon AMPK-related kinase 5. Nature 483, 608–612
20 Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin,
H. Y., Bloch, K. D. and Peterson, R. T. (2008) Dorsomorphin inhibits BMP signals
required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33–41
c© The Authors Journal compilation c© 2014 Biochemical Society© 2014 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
NUAK-selective inhibitors 225
21 Clark, K., Plater, L., Peggie, M. and Cohen, P. (2009) Use of the pharmacological inhibitor
BX795 to study the regulation and physiological roles of TBK1 and IκB kinase ε: a
distinct upstream kinase mediates Ser-172 phosphorylation and activation. J. Biol. Chem.
284, 14136–14146
22 Clark, K., Peggie, M., Plater, L., Sorcek, R. J., Young, E. R., Madwed, J. B., Hough, J.,
McIver, E. G. and Cohen, P. (2011) Novel cross-talk within the IKK family controls innate
immunity. Biochem. J. 434, 93–104
23 MacKenzie, K. F., Clark, K., Naqvi, S., McGuire, V. A., Noehren, G., Kristariyanto, Y., van
den Bosch, M., Mudaliar, M., McCarthy, P. C., Pattison, M. J. et al. (2013) PGE2 induces
macrophage IL-10 production and a regulatory-like phenotype via a protein kinase
A-SIK-CRTC3 pathway. J. Immunol. 190, 565–577
24 Durocher, Y., Perret, S. and Kamen, A. (2002) High-level and high-throughput
recombinant protein production by transient transfection of suspension-growing human
293-EBNA1 cells. Nucleic Acids Res. 30, E9
25 Sommer, E. M., Dry, H., Cross, D., Guichard, S., Davies, B. R. and Alessi, D. R. (2013)
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem. J.
452, 499–508
26 Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I.,
Arthur, J. S., Alessi, D. R. and Cohen, P. (2007) The selectivity of protein kinase
inhibitors: a further update. Biochem. J. 408, 297–315
27 Najafov, A., Sommer, E. M., Axten, J. M., Deyoung, M. P. and Alessi, D. R. (2011)
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem.
J. 433, 357–369
28 Feldman, R. I., Wu, J. M., Polokoff, M. A., Kochanny, M. J., Dinter, H., Zhu, D., Biroc,
S. L., Alicke, B., Bryant, J., Yuan, S. et al. (2005) Novel small molecule inhibitors of
3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 280, 19867–19874
29 McIver, E. G., Bryans, J., Birchall, K., Chugh, J., Drake, T., Lewis, S. J., Osborne, J.,
Smiljanic-Hurley, E., Tsang, W., Kamal, A. et al. (2012) Synthesis and structure–activity
relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon
kinases. Bioorg. Med. Chem. Lett. 22, 7169–7173
30 Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L.,
Iacob, R. E., Padera, R. et al. (2009) Novel mutant-selective EGFR kinase inhibitors
against EGFR T790M. Nature 462, 1070–1074
31 Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J. D., Patricelli,
M. P., Nomanbhoy, T. K., Alessi, D. R. and Gray, N. S. (2011) Characterization of a
selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat. Chem. Biol. 7, 203–205
32 Miduturu, C. V., Deng, X., Kwiatkowski, N., Yang, W., Brault, L., Filippakopoulos, P.,
Chung, E., Yang, Q., Schwaller, J., Knapp, S. et al. (2011) High-throughput kinase
profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem.
Biol. 18, 868–879
33 Bonn, S., Herrero, S., Breitenlechner, C. B., Erlbruch, A., Lehmann, W., Engh, R. A.,
Gassel, M. and Bossemeyer, D. (2006) Structural analysis of protein kinase
A mutants with Rho-kinase inhibitor specificity. J. Biol. Chem. 281,
24818–24830
34 Nichols, R. J., Dzamko, N., Hutti, J. E., Cantley, L. C., Deak, M., Moran, J., Bamborough,
P., Reith, A. D. and Alessi, D. R. (2009) Substrate specificity and inhibitors of LRRK2, a
protein kinase mutated in Parkinson’s disease. Biochem. J. 424, 47–60
35 Ha, J., Daniel, S., Broyles, S. S. and Kim, K. H. (1994) Critical phosphorylation sites for
acetyl-CoA carboxylase activity. J. Biol. Chem. 269, 22162–22168
36 Albini, A. (1998) Tumor and endothelial cell invasion of basement membranes. The
matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol.
Oncol. Res. 4, 230–241
Received 27 August 2013/29 October 2013; accepted 30 October 2013
Published as BJ Immediate Publication 30 October 2013, doi:10.1042/BJ20131152
c© The Authors Journal compilation c© 2014 Biochemical Society© 2014 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Biochem. J. (2014) 457, 215–225 (Printed in Great Britain) doi:10.1042/BJ20131152
SUPPLEMENTARY ONLINE DATA
Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the
LKB1-tumour-suppressor-activated NUAK kinases
Sourav BANERJEE*, Sara J. BUHRLAGE†‡, Hai-Tsang HUANG†‡, Xianming DENG†‡, Wenjun ZHOU†‡, Jinhua WANG†‡,
Ryan TRAYNOR*, Alan R. PRESCOTT§, Dario R. ALESSI*1 and Nathanael S. GRAY†‡1
*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
†Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, U.S.A.
‡Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 250 Longwood Avenue, SGM 628, Boston, MA 02115, U.S.A.
§Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
CHEMICAL SYNTHESIS
Methyl 3-amino-2-naphthoate
To a solution of 3-amino-2-naphthoic acid (562 mg, 3.0 mmol,
1.0 eq) in methanol/toluene (1:4, 10 ml) was added 2.0 M
trimethylsilyldiazomethane solution in hexane (1.8 ml, 3.6 mmol,
1.2 eq) at 0 ◦C. The reaction was stirred overnight at room
temperature (20 ◦C). Next day, the reaction was quenched with
excess acetic acid until no bubbling was seen. The mixture was
directly concentrated in vacuo. The residue was purified by silica-
gel column chromatography with ethyl acetate and hexane (0–
25% gradient, v/v) to give compound 1 (500 mg, 83%). 1H-NMR
(400 MHz, [2H]methanol) δ 8.46 (s, 1 H), 7.70 (d, J 8.2 Hz, 1 H),
7.51 (d, J 8.2 Hz, 1 H), 7.37 (ddd, J 8.2, 6.8, 1.2 Hz, 1 H), 7.15
(ddd, J 8.2, 6.8, 1.2 Hz, 1 H), 7.05 (s, 1 H), 3.93 (s, 3 H). MS
(ESI) calculated for [C12H12NO2]+ , 202; found, 202.
Methyl 3-[(2-chloro-6-methyl-5-nitropyrimidin-4-yl)amino]-2-
naphthoate
A mixture of compound 1 (480 mg, 2.4 mmol, 1.0 eq), N,N-
diisopropylethylamine (0.83 ml, 4.8 mmol, 2.0 eq) and 2,4-
dichloro-6-methyl-5-nitropyrimidine (0.76 g, 3.6 mmol, 1.5 eq)
in 2-propanol (43 ml) was stirred at room temperature overnight.
The product crashed out of 2-propanol, and was collected by
filtration and dried in vacuo. The crude compound 2 (0.79 g,
88%) was used for the next step without further purification. 1H-
NMR (400 MHz, [2H]chloroform) δ 12.04 (s, 1 H), 8.94 (s, 1 H),
8.68 (s, 1 H), 7.89 (d, J 8.2 Hz, 2 H), 7.63 (ddd, J 8.2, 7.0, 1.2 Hz,
1 H), 7.51 (ddd, J 8.2, 7.0, 1.2 Hz, 1 H), 4.05 (s, 3 H), 2.73 (s, 3 H).
MS (ESI) calculated for [C17H14ClN4O4]+ , 373; found, 373.
2-chloro-4-methyl-5,13-dihydro-6H-naphtho[2,3-e]pyrimido[5,4-
b][1,4]diazepin-6-one
To a solution of compound 2 (0.79 g, 2.1 mmol, 1.0 eq) in acetic
acid (90 ml) was added iron powder (1.7 g, 30.4 mmol, 14.5 eq).
The reaction was stirred at 60 ◦C overnight. After the reaction
was complete as monitored by reverse-phase analytical LC–MS,
the solvent was removed in vacuo. The resulting residue was
poured into ice-cold water and stirred, which resulted in a solid
precipitate that was collected by filtration, washed with water and
air-dried to give compound 3 (0.64 g, 98%). 1H-NMR (400 MHz,
[2H]chloroform) δ 8.63 (s, 1 H), 7.85 (d, J 8.2 Hz, 1 H), 7.68 (d, J
8.2 Hz, 1 H), 7.54 (ddd, J 8.2, 7.0, 1.4 Hz, 1 H), 7.42 (ddd, J 8.2,
7.0, 1.2 Hz, 1 H), 7.17 (s, 1 H), 7.15 (s, 1 H), 6.88 (s, 1 H), 2.52
(s, 3 H). MS (ESI) calculated for [C16H12ClN4O]+ , 311; found,
311.
2-chloro-4,5,13-trimethyl-5,13-dihydro-6H-naphtho[2,3-
e]pyrimido[5,4-b][1,4]diazepin-6-one
To a stirred suspension of compound 3 (0.64 g, 2.1 mmol,
1.0 eq) and methyl iodide (0.64 ml, 10.3 mmol, 5.0 eq) in dimethyl
acetamide (20.0 ml) was added sodium hydride (300 mg, 60%
suspension in mineral oil, 3.6 eq) at 0 ◦C. After the reaction
was complete as monitored by LC–MS, the solution was poured
into ice-cold water, which resulted in a solid precipitate. The
precipitate was collected by filtration, washed with water and air-
dried to give the crude product. The crude product was purified by
silica-gel column chromatography with ethyl acetate and hexane
(0–80% gradient, v/v) to give compound 4 (67 mg, 10%). 1H-
NMR (400 MHz, [2H]methanol) δ 8.30 (s, 1 H), 7.88 (d, J 8.2 Hz,
1 H), 7.84 (d, J 8.2 Hz, 1 H), 7.61 (s, 1 H), 7.54 (ddd, J 8.2, 7.0,
1 Correspondence may be addressed to either of these authors (email d.r.alessi@dundee.ac.uk or Nathanael_Gray@dfci.harvard.edu).
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1.2 Hz, 1 H), 7.45 (ddd, J 8.2, 7.0, 1.2 Hz, 1 H), 3.51 (s, 3 H), 3.37
(s, 3 H), 2.48 (s, 3 H). MS (ESI) calculated for [C18H16ClN4O]+ ,
339; found, 339.
4,5,13-trimethyl-2-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-
5,13-dihydro-6H-naphtho[2,3-e]pyrimido[5,4-b][1,4]diazepin-6-
one
A mixture of compund 4 (34 mg, 0.1 mmol, 1.0 eq), t-butyl
4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (27 mg,
0.1 mmol, 1.0 eq), X-Phos (8.6 mg, 20%), tris(dibenzyl-
ideneacetone)dipalladium(0) (11 mg, 10%) and potassium
carbonate (41.5 mg, 0.3 mmol) in 1.2 ml of t-butyl alcohol was
heated at 85 ◦C in a sealed tube for 3.5 h. The reaction was then
filtered through celite and eluted with dichloromethane. The
dichloromethane was removed in vacuo. The resulting crude
product was stirred with trifluoroacetic acid (0.38 ml, 5 mmol,
50 eq) in dichloromethane (2 ml) at room temperature overnight to
afford Boc deprotection. The solvent was removed in vacuo. The
residue was purified by reverse-phase prep-HPLC using a water
(0.05% trifuloroacetic acid)/methanol (0.05% trifluoroacetic
acid) gradient to afford the title compound HTH-01-015 as a
trifluoroacetic acid salt (18 mg, yield 31%). 1H-NMR (400 MHz,
DMSO-d6) δ 9.72–9.40 (br, 1 H), 8.74–8.61 (br, 1 H), 8.54–8.37
(br, 1 H), 8.29 (s, 1 H), 7.97 (d, J 8.2 Hz, 1 H), 7.92 (s, 1 H), 7.88
(d, J 8.2 Hz, 1 H), 7.67 (s, 1 H), 7.60 (s, 1 H), 7.56 (ddd, J 8.2,
7.0, 1.2 Hz, 1 H), 7.46 (ddd, J 8.2, 7.0, 1.2 Hz, 1 H), 4.54–4.41
(br, 1 H), 3.54–3.38 (br, 5 H), 3.27 (s, 3 H), 3.17–3.02 (br, 2
H), 2.33 (s, 3 H), 2.26–2.04 (br, 4 H). MS (ESI) calculated for
[C26H29N8O+ ]+ , 469; found, 469.
XMD18-42 and XMD17-51
XMD18-42 and XMD17-51 were synthesized following similar
strategies as shown in Scheme 1.
5,13-dimethyl-2-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-5,13-
dihydro-6H-naphtho[2,3-e]pyrimido[5,4-b][1,4]diazepin-6-one
1H-NMR (400 MHz, DMSO-d6) δ 9.77–9.44 (br, 1 H), 9.18–8.96
(br, 2 H), 8.39 (s, 1 H), 8.33 (s, 1 H), 7.98 (d, J 8.2 Hz, 1 H),
7.95 (s, 1 H), 7.91 (d, J 8.2 Hz, 1 H), 7.75 (s, 1 H), 7.60 (s, 1
H), 7.57 (t, J 8.2 Hz, 1 H), 7.46 (t, J 8.2 Hz, 1 H), 4.56–4.43
(br, 1 H), 3.55–3.47 (br, 3 H), 3.45 (s, 3 H), 3.43–3.34 (br, 2 H),
3.13–2.99 (br, 2 H), 2.27–2.09 (br, 4 H). MS (ESI) calculated for
[C25H27N8O+ ]+ , 455; found, 455.
5,11-dimethyl-2-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-5,11-
dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one
1H-NMR (400 MHz, DMSO-d6) δ 9.77–9.60 (br, 1 H), 9.16–8.94
(br, 2 H), 8.35 (s, 1 H), 7.93 (s, 1 H), 7.68 (dd, J 7.9, 1.8 Hz,
1 H), 7.58 (s, 1 H), 7.51 (td, J 7.9, 1.8 Hz, 1 H), 7.28 (d,
J 7.9 Hz, 1 H), 7.18 (t, J 7.9 Hz, 1 H), 4.52–4.44 (br, 1 H),
3.42–3.34 (br, 5 H), 3.38 (s, 3 H), 3.10–3.00 (br, 2 H), 2.21–2.12
(br, 4 H). MS (ESI) calculated for [C21H25N8O+ ]+ , 405; found,
405.
Figure S1 LI-COR quantification of the overexpression of wild-type (WT)
and inhibitor-resistant NUAK1[A195T] mutant
The Western blot signals for endogenous and overexpressed NUAK1 in HEK-293 cells
were quantified using LI-COR Odyssey technology. GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) was used as a loading control. The background signal was subtracted and
then the band intensity of overexpressed NUAK1 was divided by the signal for the endogenous
NUAK1 protein (in duplicate). Data are represented relative to the expression levels of the
endogenous protein. lower exp., lower exposure.
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Scheme S1 Synthesis of 4,5,13-trimethyl-2-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-5,13-dihydro-6H-naphtho[2,3-e]pyrimido[5,4-b][1,4]diazepin-6-
one (HTH-01-015)
Reagents and conditions: (a) trimethylsilyldiazomethane (1.2 eq.), methanol/toluene (1:4), 0◦C; (b) N,N-diisopropylethylamine (2.0 eq), 2-propanol; (c) Fe (14.5 eq.), acetic acid, 60◦C; (d) methyl
iodide (5.0 eq.), sodium hydride (3.6 eq.), dimethyl acetamide, 0◦C; (e) X-Phos (20 % mol), tris(dibenzylideneacetone)dipalladium(0) (10 % mol), potassium carbonate (3.0 eq.), t-butyl alcohol,
85◦C; (f) trifluoroacetic acid (50 eq), dichloromethane.
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Table S1 Effect of the NUAK inhibitors upon the activity of 140 protein
kinases
Results are presented as the percentage of kinase activity in DMSO control reactions. Protein
kinases were assayed in vitro with 0.1 or 1 μM of the inhibitors as described previously
[1], and the results are means +− S.D. for triplicate reactions. *Indicates AMPK-related
kinase family members. Abbreviations are as follows: ABL, Abelson tyrosine-protein kinase
1; AMPK, AMP-activated protein kinase; ASK, apoptosis signal-regulating kinase; BRK,
breast tumour kinase; BRSK, brain-specific kinase; BTK, Bruton”s tyrosine kinase; CaMK,
calmodulin-dependent kinase; CaMKK, CaMK kinase; CDK, cyclin-dependent kinase; CHK,
checkpoint kinase; CK, casein kinase; CLK, CDC-like kinase; CSK, C-terminal Src kinase;
DAPK, death-associated protein kinase; DDR, discoidin domain receptor; DYRK, dual-specificity
tyrosine-phosphorylated and regulated kinase; EF2K, elongation-factor-2 kinase; EIF2AK,
eukaryotic translation initiation factor 2-alpha kinase; EPH, ephrin; ERK, extracellular
signal-regulated kinase; FGF-R, fibroblast growth factor receptor; GCK, germinal centre
kinase; GSK, glycogen synthase kinase; HER, human epidermal growth factor receptor;
HIPK, homeodomain-interacting protein kinase; IGF1R, IGF1 receptor; IKK, inhibitory
κB kinase; IR, insulin receptor; IRAK, interleukin-1 receptor-associated kinase; IRR,
insulin-related receptor; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; Lck, lymphocyte
cell-specific protein tyrosine kinase; LKB1, liver kinase B1; MAPK, mitogen-activated
protein kinase; MAPKAP-K, MAPK-activated protein kinase; MARK, microtubule-affinity-
regulating kinase; MEKK, MAP kinase kinase kinase; MELK, maternal embryonic leucine-
zipper kinase; MINK, misshapen/NIK-related kinase; MKK, MAPK kinase; MLK, mixed lineage
kinase; MNK, MAPK-integrating protein kinase; MPSK, myristoylated and palmitoylated
serine/threonine-protein kinase; MSK, mitogen- and stress-activated protein kinase; MST,
mammalian homologue Ste20-like kinase; NEK, NIMA (never in mitosis in Aspergillus
nidulans)-related kinase; NUAK, novel (NUA) family SnF1-like kinase; OSR, oxidative
stress-responsive kinase; PAK, p21-activated protein kinase; PDGFRA, platelet-derived growth
factor receptor-α; PDK, phosphoinositide-dependent kinase; PHK, phosphorylase kinase; PIM,
provirus integration site for Moloney murine leukaemia virus; PINK (insect homologue),
PTEN-induced kinase; PKA, cAMP-dependent protein kinase; PKB, protein kinase B; PKC,
protein kinase C; PKD, protein kinase D; PLK, polo-like kinase; PRAK, p38-regulated activated
kinase; PRK, protein kinase C-related kinase; RIPK, receptor-interacting protein kinase; ROCK,
Rho-dependent protein kinase; RSK, ribosomal S6 kinase; S6K, p70 ribosomal S6 kinase; SGK,
serum- and glucocorticoid-induced protein kinase; SIK, salt-induced kinase; smMLCK, smooth
muscle myosin light-chain kinase; SRPK, serine/arginine protein kinase; STK, serine/threonine
kinase; SYK, spleen tyrosine kinase; TAK, TGFβ-activated kinase; TAO, thousand and one amino
acid; TBK1, TANK-binding kinase 1; TESK, testis-specific protein kinase; TGFBR, TGFβ receptor;
TIE, tyrosine-protein kinase receptor; TLK, tousled-like kinase; TrkA, tropomyocin receptor
kinase; TSSK, testis-specific serine/threonine-protein kinase; TTBK, tau-tubulin kinase; ULK,
Unc-51-like kinase; VEGFR, vascular endothelial growth factor receptor; WNK, with no lysine;
YES1, Yamaguchi sarcoma viral oncogene homologue 1; ZAP, ζ -chain-associated protein.
Kinase HTH-01-015 WZ4003
NUAK1* 11+− 0 6+− 0
AMPK* 127 +− 9 89 +− 9
MARK1* 106 +− 4 76 +− 9
MARK2* 99 +− 4 85 +− 14
MARK3* 102 +− 1 51 +− 2
MARK4* 75 +− 2 79 +− 3
BRSK1* 130 +− 32 91 +− 1
BRSK2* 97 +− 3 75 +− 22
MELK* 99 +− 9 70 +− 2
SIK2* 112 +− 16 70 +− 0
SIK3* 109 +− 32 102 +− 9
LKB1 98 +− 10 87 +− 0
MKK1 113 +− 28 98 +− 14
MKK2 111 +− 10 98 +− 4
MKK6 87 +− 1 101 +− 4
ERK1 83 +− 1 94 +− 2
ERK2 125 +− 6 107 +− 6
ERK5 121 +− 4 79 +− 2
JNK1 100 +− 2 88 +− 4
JNK2 130 +− 9 97 +− 3
JNK3 101 +− 8 70 +− 2
p38α MAPK 118 +− 4 95 +− 4
p38β MAPK 112 +− 3 104 +− 6
p38γ MAPK 100 +− 0 91 +− 0
p38δ MAPK 113 +− 1 63 +− 10
ERK8 98 +− 7 90 +− 9
RSK1 93 +− 3 67 +− 5
Table S1 Continued
Kinase HTH-01-015 WZ4003
RSK2 106 +− 15 76 +− 1
PDK1 102 +− 5 104 +− 10
PKBα 87 +− 15 98 +− 3
PKBβ 104 +− 2 114 +− 34
SGK1 97 +− 2 99 +− 7
S6K1 85 +− 3 83 +− 14
PKA 101 +− 0 84 +− 18
ROCK 2 110 +− 14 80 +− 2
PRK2 112 +− 8 99 +− 20
PKCα 117 +− 4 77 +− 8
PKCγ 107 +− 0 103 +− 15
PKCζ 98 +− 13 86 +− 15
PKD1 94 +− 8 57 +− 5
STK33 93 +− 2 33 +− 7
MSK1 111 +− 2 90 +− 3
MNK1 102 +− 9 104 +− 8
MNK2 106 +− 0 84 +− 16
MAPKAP-K2 118 +− 9 82 +− 10
MAPKAP-K3 96 +− 20 91 +− 5
PRAK 105 +− 10 94 +− 0
CAMKKβ 87 +− 12 44 +− 2
CAMK1 92 +− 0 81 +− 1
SmMLCK 77 +− 8 78 +− 2
PHK 104 +− 24 54 +− 11
DAPK1 100 +− 5 93 +− 12
CHK1 106 +− 6 58 +− 1
CHK2 105 +− 11 40 +− 0
GSK3β 119 +− 13 88 +− 0
CDK2-Cyclin A 96 +− 3 90 +− 32
CDK9-Cyc T1 68 +− 1 89 +− 2
PLK1 98 +− 5 84 +− 9
Aurora A 117 +− 1 75 +− 11
Aurora B 97 +− 13 72 +− 8
TLK1 106 +− 10 91 +− 7
TSSK1 95 +− 7 58 +− 11
CK1γ 2 109 +− 11 102 +− 4
CK1δ 94 +− 5 97 +− 5
CK2 120 +− 11 76 +− 0
TTBK1 124 +− 19 78 +− 21
TTBK2 102 +− 4 89 +− 3
DYRK1A 89 +− 4 102 +− 2
DYRK2 113 +− 7 66 +− 8
DYRK3 98 +− 0 71 +− 9
NEK2α 103 +− 2 110 +− 3
NEK6 99 +− 13 79 +− 13
IKKβ 81 +− 9 72 +− 0
IKKε 85 +− 1 104 +− 0
TBK1 112 +− 8 84 +− 5
PIM1 92 +− 4 79 +− 7
PIM2 106 +− 6 101 +− 21
PIM3 97 +− 2 98 +− 1
SRPK1 103 +− 7 94 +− 1
EF2K 103 +− 8 91 +− 2
EIF2AK3 99 +− 13 76 +− 17
HIPK1 107 +− 7 103 +− 20
HIPK2 107 +− 6 86 +− 19
HIPK3 96 +− 13 91 +− 1
CLK2 54 +− 1 65 +− 7
PAK2 125 +− 13 92 +− 6
PAK4 110 +− 8 69 +− 6
PAK5 95 +− 5 89 +− 5
PAK6 95 +− 2 104 +− 1
MST2 118 +− 1 91 +− 2
MST3 111 +− 3 93 +− 8
MST4 119 +− 7 101 +− 0
GCK 126 +− 3 96 +− 4
MAP4K3 127 +− 5 111 +− 15
MAP4K5 106 +− 4 108 +− 2
MINK1 101 +− 1 120 +− 5
MEKK1 110 +− 14 91 +− 1
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Table S1 Continued
Kinase HTH-01-015 WZ4003
MLK1 102 +− 18 69 +− 0
MLK3 94 +− 7 73 +− 8
TESK1 106 +− 8 98 +− 12
TAO1 123 +− 10 101 +− 7
ASK1 105 +− 2 107 +− 7
TAK1 109 +− 7 85 +− 10
IRAK1 103 +− 2 88 +− 2
IRAK4 103 +− 11 92 +− 3
RIPK2 88 +− 4 105 +− 0
OSR1 107 +− 4 89 +− 1
TTK 118 +− 3 54 +− 17
MPSK1 103 +− 5 107 +− 9
WNK1 99 +− 7 95 +− 7
ULK1 132 +− 19 52 +− 2
ULK2 106 +− 13 37 +− 2
TGFBR1 102 +− 13 102 +− 7
Src 76 +− 8 109 +− 10
Lck 90 +− 3 99 +− 3
CSK 103 +− 5 105 +− 0
YES1 76 +− 7 89 +− 5
ABL 110 +− 3 104 +− 9
BTK 109 +− 4 114 +− 14
JAK2 101 +− 11 65 +− 2
SYK 125 +− 5 93 +− 4
ZAP70 103 +− 2 89 +− 6
TIE2 84 +− 12 94 +− 0
BRK 96 +− 0 79 +− 0
EPH-A2 84 +− 1 91 +− 13
EPH-A4 94 +− 8 106 +− 7
EPH-B1 97 +− 15 98 +− 3
EPH-B2 97 +− 15 107 +− 13
EPH-B3 120 +− 1 113 +− 39
EPH-B4 102 +− 4 83 +− 2
FGF-R1 105 +− 11 66 +− 2
HER4 102 +− 5 76 +− 22
IGF-1R 133 +− 26 33 +− 4
IR 105 +− 0 92 +− 12
IRR 106 +− 6 88 +− 2
TrkA 82 +− 1 85 +− 2
DDR2 91 +− 5 86 +− 21
VEG-FR 97 +− 12 74 +− 21
PDGFRA 109 +− 5 96 +− 2
PINK 99 +− 1 95 +− 7
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